ADRO Aduro Biotech Inc.

1.41
+0.01  (+1%)
Previous Close 1.4
Open 1.4
Price To Book 1.38
Market Cap 113,525,387
Shares 80,514,459
Volume 834,744
Short Ratio
Av. Daily Volume 948,150
Stock charts supplied by TradingView

NewsSee all news

  1. Aduro Biotech Announces Corporate Restructuring

    BERKELEY, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the immune system cGAS-STING and APRIL

  2. Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results

    BERKELEY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and

  3. Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

    BERKELEY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and

  4. Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the 2019 Cantor Global

  5. Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

    BERKELEY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial
Pancreatic cancer
Phase 1b initiation announced June 7, 2018.
ADU-214 with Nivolumab
Non-Small Cell Lung Cancer
Phase 1 trial to be discontinued - noted December 17, 2019.
ADU-S100 and Spartalizumab
Solid tumors or lymphomas
Phase 1 enrolment to be terminated - noted December 17, 2019.
ADU-S100 and ipilimumab
Melanoma
Phase 1 data due 1H 2020 in healthy volunteers and 2H 2020 in IgA Nephropathy patients.
BION-1301
IgA Nephropathy
Phase 2 data due 2H 2020.
ADU-S100 and pembrolizumab
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase 1 data presented at SITC November 2019 noted one patient in each of the monotherapy and combo arms showed a partial response.
MK-5890 and pembrolizumab
Solid tumors

Latest News

  1. Aduro Biotech Announces Corporate Restructuring

    BERKELEY, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the immune system cGAS-STING and APRIL

  2. Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results

    BERKELEY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and

  3. Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

    BERKELEY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and

  4. Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the 2019 Cantor Global

  5. Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

    BERKELEY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING)

  6. Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    BERKELEY, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the